Skip to content

A clinical trial to compare the effects of two drugs, Ceftriaxone and Benzathine Penicillin in the treatment of Early stage of the sexually transmitted disease, Syphilis

A comparative study of Injection Benzathine Penicillin and Injection Ceftriaxone in the management of Early Syphilis - NILL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/071014
Enrollment
60
Registered
2024-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A519- Early syphilis, unspecified

Interventions

Intervention1: Injection Ceftriaxone: Injection Ceftriaxone 1 gram Intravenously for 10 days Control Intervention1: Injection Benzathine Penicillin: Single Dose of Injection Benzathine Penicillin 2.4

Sponsors

Government Tirunelveli Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients who present in STD Clinics with untreated Early syphilis (Includes Primary, Secondary and Early latent syphilis). Operational definition for Early syphilis – 1 year from the primary lesion(chancre) or if there is no primary chancre 1 year from the date of last contact with REACTIVE RPR & Confirmed by POSITIVE TPHA

Exclusion criteria

Exclusion criteria: 1. Positive skin-test reaction to penicillin antigen and ceftriaxone antigen 2. History of penicillin and ceftriaxone allergy 3. Patients who have received any other antibiotics before initiation of treatment 4. Patients with Late latent syphilis and Tertiary syphilis

Design outcomes

Primary

MeasureTime frame
Serological response as defined as a four fold decrease in the initial RPR titre within 6 months of treatmentTimepoint: Serological response as defined as a four fold decrease in the initial RPR titre within 6 months of treatment

Secondary

MeasureTime frame
Comparing the time taken for RPR to fall in both groups and to monitor for Adverse events if any in both groupsTimepoint: 6 months

Countries

India

Contacts

Public ContactDr Briswin Jino B G

Government Tirunelveli Medical College

drmselvakumar71@gmail.com9894308296

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026